⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2026ESMO OpenOpen Access

85eP Targeting regulatory T cells in solid tumors: A clinical development analysis of 55 drug candidates

Gabriel Schnetzler S.M. Le Claire N. Bezman

View Full Paper

Ask AI

Bookmark

Share

Key Points

Evaluate the safety profiles of 55 drug candidates targeting regulatory T cells in solid tumors, focusing on PD-1 inhibitors.
Analyzed reports from the FAERS database regarding PD-1 inhibitors
Calculated disproportionality of adverse events for individual drugs
Identified toxicities associated with Pembrolizumab and Cemiplimab
2.7% of identified reports included adverse events related to PD-1 inhibitors
Cemiplimab showed high disproportionality for specific toxicities like myasthenia gravis and myocarditis
Pembrolizumab had the strongest signal for Triple-3M syndrome with a ROR of 218.57

Implication

Clinical analysis reveals toxicities related to PD-1 inhibitors in solid tumors, suggesting critical management strategies.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schnetzler et al. (2026) studied this question.

synapsesocial.com/papers/69d0adc2659487ece0fa44a0 https://doi.org/10.1016/j.esmoop.2026.106226

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Abstract B029: Differential safety profiles of PD-1 inhibitors: A comparative pharmacovigilance analysis of immune-related adverse events with pembrolizumab and nivolumab in FAERS (2015–2024)Human Clinical Trial · 2026
2Triple-M Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A FAERS Pharmacovigilance AnalysisOriginal Research · 2026
35PSQ-062 Safety evaluation of pembrolizumab in monotherapy2024
4Multidimensional Assessment of Neurological Adverse Reactions Related to <scp>PD</scp> ‐1 Inhibitors: A Real‐World Pharmacovigilance StudyClinical Trial · 2026 · 1 citations
5Treatment-related adverse events of PD-1 versus PD-L1 inhibitors commonly used in lung cancer therapy: Analysis of real-world FAERS data.2024

5PSQ-034 Comparison of toxicity in clinical practice of anti-PD-1/PD-L1 antibodies in monotherapy in non-small-cell lung cancer2024
Hepatobiliary Adverse Events Linked to Immune Checkpoint Inhibitors: A Real‐World Pharmacovigilance Analysis Using <scp>FAERS</scp> Data2025
PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancerESMO Open · 2026
Risk stratification by circulating tumor DNA-based pretreatment genomic profile and post-operative molecular residual disease detection in resectable colorectal oligometastases: PRECISION, a prospective multicenter studyESMO Open · 2026

More from ESMO Open

More from Roche (Switzerland)

More from Hôpital Privé Jean Mermo

More from Acentech (United States)